title: [Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women].
abstract: OBJECTIVE
  To study the efficacy of alendronate to prevent hip fracture risk of postmenopausal women.
  
  
  METHODS
  Randomized controlled trials in postmenopausal women receiving alendronate or placebo for preventing hip fractures rate were searched from Medline, EMBASE, Cochrane Trial Registry and China Biological Medicine database between January 1980 to December 2007. Key words included hip fractures, alendronate, postmenopausal and placebo-controlled. Language was limited in English and Chinese. The software Revman 4.2 was used to perform meta-analysis.
  
  
  RESULTS
  Six trials, which included 8610 postmenopausal women, met all our inclusion criteria Meta-analysis showed that alendronate can decrease hip fracture rate (OR = 0.51, 95% CI: 0.34, 0.77).
  
  
  CONCLUSIONS
  Alendronate can reduce significantly hip fracture rate in postmenopausal women.
authors: Orthopedic Department, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China. terrence_yuan@yahoo.com.cn
authors: Ting
authors: T
authors: Yuan
authors: Xiao-lin
authors: XL
authors: Li
authors: Chang-qing
authors: CQ
authors: Zhang
authors: Hui-peng
authors: HP
authors: Shi
authors: Bing-fang
authors: BF
authors: Zeng
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control*; D006801:Humans; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D019386:Alendronate